EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer
Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuxim...
Saved in:
| Published in | Nanoscale Vol. 1; no. 35; pp. 16738 - 16749 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Royal Society of Chemistry
13.09.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable
in vivo
tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy.
The epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. |
|---|---|
| AbstractList | Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable
in vivo
tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy.
The epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable in vivo tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy. Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable in vivo tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy. Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable in vivo tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy.Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable in vivo tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy. |
| Author | Li, Yuan Jin, Zhengyu Sun, Ting Du, Yang Liang, Xiaolong Xue, Huadan Tian, Jie |
| AuthorAffiliation | Chinese Academy of Sciences CAS Key laboratory of Molecular Imaging Department of Ultrasound The State Key Laboratory of Management and Control for Complex Systems Peking University Third Hospital Department of Radiology Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Automation University of Chinese Academy of Sciences |
| AuthorAffiliation_xml | – sequence: 0 name: CAS Key laboratory of Molecular Imaging – sequence: 0 name: Peking Union Medical College Hospital – sequence: 0 name: Department of Radiology – sequence: 0 name: Chinese Academy of Sciences – sequence: 0 name: Institute of Automation – sequence: 0 name: Department of Ultrasound – sequence: 0 name: Peking University Third Hospital – sequence: 0 name: Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 0 name: The State Key Laboratory of Management and Control for Complex Systems – sequence: 0 name: University of Chinese Academy of Sciences |
| Author_xml | – sequence: 1 givenname: Yuan surname: Li fullname: Li, Yuan – sequence: 2 givenname: Yang surname: Du fullname: Du, Yang – sequence: 3 givenname: Xiaolong surname: Liang fullname: Liang, Xiaolong – sequence: 4 givenname: Ting surname: Sun fullname: Sun, Ting – sequence: 5 givenname: Huadan surname: Xue fullname: Xue, Huadan – sequence: 6 givenname: Jie surname: Tian fullname: Tian, Jie – sequence: 7 givenname: Zhengyu surname: Jin fullname: Jin, Zhengyu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30156250$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1v1DAQhi1URD_gwh1kiQtCCkzs2M5yg1VbkCqQKjhHzmTCuiT2YjuH_gT-Nd5uWaSKy8xo9MyH3plTduSDJ8ae1_C2Brl6h62PoFqQ_SN2IqCBSkojjg6xbo7ZaUo3AHoltXzCjiXUSgsFJ-z3-eXFdZVt_EGZBj65bUhhthP31ofNbR_dwJGiLUlK73nelNiHlB3ycfGYXfDc-oG7eV48cdwQ_twG5zN3fuN6dwe4wvA5LImKHWjiYeQYphAJcxmF1pcRT9nj0U6Jnt37M_b94vzb-lN19fXy8_rDVYUNyFypAZCoVVTXGlA2ZtVa04zC9lqANi02xgx9q6lFPSqpaoEoTGNas5JyKJkz9nrfdxvDr4VS7maXkKbJeiordgJWWimhzQ599QC9CUv0ZbtOFOUbJUBBoV7eU0s_09Bto5ttvO3-ilyAN3sAY0gp0nhAauh2F-zW7Zfruwt-LDA8gNFlu5MxR-um_5e82JfEhIfW_55C_gGagafP |
| CitedBy_id | crossref_primary_10_1002_wnan_1660 crossref_primary_10_1016_j_pmatsci_2020_100768 crossref_primary_10_1039_D1NR06053H crossref_primary_10_1002_gch2_202000123 crossref_primary_10_1016_j_jconrel_2024_08_051 crossref_primary_10_1021_acsbiomaterials_9b00690 crossref_primary_10_1021_acsbiomaterials_1c00765 crossref_primary_10_3390_ijms24043632 crossref_primary_10_1002_adtp_201900101 crossref_primary_10_1016_j_ejmcr_2024_100137 crossref_primary_10_1007_s12253_019_00737_7 crossref_primary_10_1186_s12935_024_03610_z crossref_primary_10_3390_pharmaceutics15051514 crossref_primary_10_1080_08982104_2021_1903035 crossref_primary_10_3390_pharmaceutics14020241 crossref_primary_10_1002_btm2_10601 crossref_primary_10_1038_s41401_019_0281_1 crossref_primary_10_1016_j_ccr_2023_215350 crossref_primary_10_1039_D0NR02393K crossref_primary_10_1142_S1088424620300098 crossref_primary_10_2217_nnm_2022_0214 crossref_primary_10_1002_advs_202002253 crossref_primary_10_1016_j_bioadv_2023_213556 crossref_primary_10_1016_j_actbio_2021_03_055 crossref_primary_10_3390_vaccines10040499 crossref_primary_10_3390_biomedicines9091075 crossref_primary_10_1186_s12938_022_01012_8 crossref_primary_10_3390_nano15030158 crossref_primary_10_1111_php_13173 crossref_primary_10_1016_j_cej_2020_124268 crossref_primary_10_1002_adma_202416899 crossref_primary_10_1002_wnan_1605 crossref_primary_10_1557_jmr_2020_321 crossref_primary_10_1155_2022_2431026 crossref_primary_10_3390_ph11040133 crossref_primary_10_1016_j_semcancer_2019_06_017 crossref_primary_10_1002_advs_201903394 crossref_primary_10_1016_j_ijpharm_2021_121134 crossref_primary_10_1016_j_matdes_2021_109958 crossref_primary_10_3390_pharmaceutics14010120 crossref_primary_10_1007_s00018_019_03305_z crossref_primary_10_1002_advs_202100876 crossref_primary_10_1016_j_pdpdt_2024_104464 crossref_primary_10_1515_nanoph_2021_0241 crossref_primary_10_3390_ph14050447 crossref_primary_10_1039_C8CS00896E crossref_primary_10_1016_j_intimp_2021_107607 crossref_primary_10_1016_j_apmt_2021_101003 crossref_primary_10_1039_D0TB01052A crossref_primary_10_1016_j_pdpdt_2019_01_004 crossref_primary_10_1021_acs_chemrev_3c00062 |
| Cites_doi | 10.1021/acs.bioconjchem.5b00318 10.1056/NEJMoa1003466 10.1146/annurev.immunol.23.021704.115611 10.1021/jacs.6b09538 10.1016/j.mri.2006.03.009 10.1016/j.biomaterials.2015.10.048 10.1016/j.canlet.2017.03.030 10.1161/CIRCIMAGING.108.801712 10.1155/2015/158038 10.1002/anie.201103557 10.1159/000445335 10.1021/acsami.5b07856 10.1155/2015/149014 10.1039/C6CC02571D 10.1002/adma.201705350 10.1016/j.cis.2013.11.014 10.7150/thno.14792 10.1039/b926367e 10.18632/oncotarget.9482 10.3390/ph7030311 10.7150/thno.9899 10.1093/annonc/mdw416 10.1016/j.canlet.2017.11.019 10.1016/j.ejrad.2006.06.021 10.1016/j.humimm.2011.07.312 10.1200/JCO.2016.66.9861 10.1016/j.canlet.2012.11.044 10.7150/thno.7341 |
| ContentType | Journal Article |
| Copyright | Copyright Royal Society of Chemistry 2018 |
| Copyright_xml | – notice: Copyright Royal Society of Chemistry 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7SR 7U5 8BQ 8FD F28 FR3 JG9 L7M 7X8 |
| DOI | 10.1039/c8nr05803b |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Engineered Materials Abstracts Solid State and Superconductivity Abstracts METADEX Technology Research Database ANTE: Abstracts in New Technology & Engineering Engineering Research Database Materials Research Database Advanced Technologies Database with Aerospace MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Materials Research Database Engineered Materials Abstracts Technology Research Database Solid State and Superconductivity Abstracts Engineering Research Database Advanced Technologies Database with Aerospace ANTE: Abstracts in New Technology & Engineering METADEX MEDLINE - Academic |
| DatabaseTitleList | CrossRef Materials Research Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 2040-3372 |
| EndPage | 16749 |
| ExternalDocumentID | 30156250 10_1039_C8NR05803B c8nr05803b |
| Genre | Journal Article |
| GroupedDBID | --- -JG 0-7 0R~ 29M 4.4 53G 705 7~J AAEMU AAIWI AAJAE AANOJ AARTK AAWGC AAXHV ABASK ABDVN ABEMK ABJNI ABPDG ABRYZ ABXOH ACGFS ACIWK ACLDK ADMRA ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFRDS AFVBQ AGEGJ AGRSR AGSTE AHGCF AKBGW ALMA_UNASSIGNED_HOLDINGS ANUXI APEMP ASKNT AUDPV AZFZN BLAPV BSQNT C6K DU5 EBS ECGLT EE0 EF- EJD F5P GGIMP H13 HZ~ H~N J3I O-G O9- OK1 P2P RAOCF RCNCU RNS RPMJG RRC RSCEA RVUXY AAYXX ABIQK ACRPL ADNMO AFRZK AGQPQ AHGXI AKMSF ALSGL ALUYA ANBJS ANLMG ASPBG AVWKF CAG CITATION COF FEDTE HVGLF J3G J3H L-8 R56 CGR CUY CVF ECM EIF NPM 7SR 7U5 8BQ 8FD F28 FR3 JG9 L7M 7X8 |
| ID | FETCH-LOGICAL-c403t-5d0cee85e1160c34798a74f2ab620678c477db86e8c6f53512cc274787933df53 |
| ISSN | 2040-3364 2040-3372 |
| IngestDate | Thu Jul 10 21:59:36 EDT 2025 Mon Jun 30 04:34:03 EDT 2025 Mon Jul 21 06:06:24 EDT 2025 Tue Jul 01 01:13:27 EDT 2025 Thu Apr 24 23:03:33 EDT 2025 Tue Dec 17 21:00:37 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 35 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c403t-5d0cee85e1160c34798a74f2ab620678c477db86e8c6f53512cc274787933df53 |
| Notes | 10.1039/c8nr05803b Electronic supplementary information (ESI) available. See DOI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0588-2703 |
| PMID | 30156250 |
| PQID | 2103452050 |
| PQPubID | 2047485 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2096552675 proquest_journals_2103452050 crossref_primary_10_1039_C8NR05803B crossref_citationtrail_10_1039_C8NR05803B rsc_primary_c8nr05803b pubmed_primary_30156250 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20180913 |
| PublicationDateYYYYMMDD | 2018-09-13 |
| PublicationDate_xml | – month: 9 year: 2018 text: 20180913 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Cambridge |
| PublicationTitle | Nanoscale |
| PublicationTitleAlternate | Nanoscale |
| PublicationYear | 2018 |
| Publisher | Royal Society of Chemistry |
| Publisher_xml | – name: Royal Society of Chemistry |
| References | Kocian (C8NR05803B-(cit3)/*[position()=1]) 2011; 72 Sihver (C8NR05803B-(cit7)/*[position()=1]) 2014; 7 Bao (C8NR05803B-(cit4)/*[position()=1]) 2016; 76 Yue (C8NR05803B-(cit19)/*[position()=1]) 2014; 207 Gonzalez-Pons (C8NR05803B-(cit2)/*[position()=1]) 2015; 2015 Liang (C8NR05803B-(cit12)/*[position()=1]) 2011; 50 Sirol (C8NR05803B-(cit27)/*[position()=1]) 2009; 2 Jin (C8NR05803B-(cit5)/*[position()=1]) 2017; 397 Zhang (C8NR05803B-(cit18)/*[position()=1]) 2018; 30 Gao (C8NR05803B-(cit14)/*[position()=1]) 2016; 6 Hodi (C8NR05803B-(cit15)/*[position()=1]) 2010; 363 Zhang (C8NR05803B-(cit6)/*[position()=1]) 2016; 52 Duan (C8NR05803B-(cit13)/*[position()=1]) 2016; 138 Jacobs (C8NR05803B-(cit1)/*[position()=1]) 2015; 2015 Xing (C8NR05803B-(cit9)/*[position()=1]) 2014; 4 Rizvi (C8NR05803B-(cit28)/*[position()=1]) 2016; 34 Chi (C8NR05803B-(cit8)/*[position()=1]) 2014; 4 Natarajan (C8NR05803B-(cit20)/*[position()=1]) 2015; 26 Du (C8NR05803B-(cit25)/*[position()=1]) 2018; 414 Jing (C8NR05803B-(cit21)/*[position()=1]) 2015; 7 Liu (C8NR05803B-(cit24)/*[position()=1]) 2013; 330 Cao (C8NR05803B-(cit22)/*[position()=1]) 2010; 46 Ke (C8NR05803B-(cit26)/*[position()=1]) 2006; 24 Greenwald (C8NR05803B-(cit17)/*[position()=1]) 2005; 23 Key (C8NR05803B-(cit10)/*[position()=1]) 2014; 9 Kanda (C8NR05803B-(cit29)/*[position()=1]) 2016; 27 Cai (C8NR05803B-(cit23)/*[position()=1]) 2016; 7 Bedognetti (C8NR05803B-(cit16)/*[position()=1]) 2016; 11 Bellin (C8NR05803B-(cit11)/*[position()=1]) 2006; 60 |
| References_xml | – volume: 26 start-page: 2062 issue: 10 year: 2015 ident: C8NR05803B-(cit20)/*[position()=1] publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.5b00318 – volume: 363 start-page: 711 issue: 8 year: 2010 ident: C8NR05803B-(cit15)/*[position()=1] publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 23 start-page: 515 year: 2005 ident: C8NR05803B-(cit17)/*[position()=1] publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.23.021704.115611 – volume: 138 start-page: 16686 issue: 51 year: 2016 ident: C8NR05803B-(cit13)/*[position()=1] publication-title: J. Am. Chem. Soc. doi: 10.1021/jacs.6b09538 – volume: 24 start-page: 931 issue: 7 year: 2006 ident: C8NR05803B-(cit26)/*[position()=1] publication-title: Magn. Reson. Imaging doi: 10.1016/j.mri.2006.03.009 – volume: 76 start-page: 11 year: 2016 ident: C8NR05803B-(cit4)/*[position()=1] publication-title: Biomaterials doi: 10.1016/j.biomaterials.2015.10.048 – volume: 397 start-page: 61 year: 2017 ident: C8NR05803B-(cit5)/*[position()=1] publication-title: Cancer Lett. doi: 10.1016/j.canlet.2017.03.030 – volume: 2 start-page: 391 issue: 5 year: 2009 ident: C8NR05803B-(cit27)/*[position()=1] publication-title: Circ. Cardiovasc. Imaging doi: 10.1161/CIRCIMAGING.108.801712 – volume: 2015 start-page: 158038 year: 2015 ident: C8NR05803B-(cit1)/*[position()=1] publication-title: J. Immunol. Res. doi: 10.1155/2015/158038 – volume: 50 start-page: 11622 issue: 49 year: 2011 ident: C8NR05803B-(cit12)/*[position()=1] publication-title: Angew. Chem., Int. Ed. doi: 10.1002/anie.201103557 – volume: 11 start-page: 108 issue: 2 year: 2016 ident: C8NR05803B-(cit16)/*[position()=1] publication-title: Breast Care doi: 10.1159/000445335 – volume: 7 start-page: 22095 issue: 39 year: 2015 ident: C8NR05803B-(cit21)/*[position()=1] publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.5b07856 – volume: 2015 start-page: 149014 year: 2015 ident: C8NR05803B-(cit2)/*[position()=1] publication-title: BioMed Res. Int. doi: 10.1155/2015/149014 – volume: 52 start-page: 7939 issue: 51 year: 2016 ident: C8NR05803B-(cit6)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/C6CC02571D – volume: 30 issue: 7 year: 2018 ident: C8NR05803B-(cit18)/*[position()=1] publication-title: Adv. Mater. doi: 10.1002/adma.201705350 – volume: 207 start-page: 32 year: 2014 ident: C8NR05803B-(cit19)/*[position()=1] publication-title: Adv. Colloid Interface Sci. doi: 10.1016/j.cis.2013.11.014 – volume: 6 start-page: 627 issue: 5 year: 2016 ident: C8NR05803B-(cit14)/*[position()=1] publication-title: Theranostics doi: 10.7150/thno.14792 – volume: 46 start-page: 5265 issue: 29 year: 2010 ident: C8NR05803B-(cit22)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/b926367e – volume: 7 start-page: 40047 issue: 26 year: 2016 ident: C8NR05803B-(cit23)/*[position()=1] publication-title: Oncotarget doi: 10.18632/oncotarget.9482 – volume: 7 start-page: 311 issue: 3 year: 2014 ident: C8NR05803B-(cit7)/*[position()=1] publication-title: Pharmaceuticals doi: 10.3390/ph7030311 – volume: 4 start-page: 1072 issue: 11 year: 2014 ident: C8NR05803B-(cit8)/*[position()=1] publication-title: Theranostics doi: 10.7150/thno.9899 – volume: 27 start-page: 2242 issue: 12 year: 2016 ident: C8NR05803B-(cit29)/*[position()=1] publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw416 – volume: 414 start-page: 230 year: 2018 ident: C8NR05803B-(cit25)/*[position()=1] publication-title: Cancer Lett. doi: 10.1016/j.canlet.2017.11.019 – volume: 9 start-page: 711 year: 2014 ident: C8NR05803B-(cit10)/*[position()=1] publication-title: Int. J. Nanomed. – volume: 60 start-page: 314 issue: 3 year: 2006 ident: C8NR05803B-(cit11)/*[position()=1] publication-title: Eur. J. Radiol. doi: 10.1016/j.ejrad.2006.06.021 – volume: 72 start-page: 1022 issue: 11 year: 2011 ident: C8NR05803B-(cit3)/*[position()=1] publication-title: Hum. Immunol. doi: 10.1016/j.humimm.2011.07.312 – volume: 34 start-page: 2969 issue: 25 year: 2016 ident: C8NR05803B-(cit28)/*[position()=1] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.66.9861 – volume: 330 start-page: 200 issue: 2 year: 2013 ident: C8NR05803B-(cit24)/*[position()=1] publication-title: Cancer Lett. doi: 10.1016/j.canlet.2012.11.044 – volume: 4 start-page: 290 issue: 3 year: 2014 ident: C8NR05803B-(cit9)/*[position()=1] publication-title: Theranostics doi: 10.7150/thno.7341 |
| SSID | ssj0069363 |
| Score | 2.501458 |
| Snippet | Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an... |
| SourceID | proquest pubmed crossref rsc |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 16738 |
| SubjectTerms | Animals Anticancer properties B7-H1 Antigen Cell Line, Tumor Cetuximab - administration & dosage Colorectal Neoplasms - diagnostic imaging Colorectal Neoplasms - drug therapy Drug Carriers ErbB Receptors - metabolism Gadolinium Growth factors Immunotherapy Liposomes Male Medical imaging Mice Mice, Inbred BALB C Monoclonal antibodies Nanoparticles Optical Imaging Photochemotherapy Photodynamic therapy Porphyrins Targeted cancer therapy Theranostic Nanomedicine Tumors |
| Title | EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30156250 https://www.proquest.com/docview/2103452050 https://www.proquest.com/docview/2096552675 |
| Volume | 1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLdgu8AB8TVWGMgILqjKcGM7cbhto90EpUijFeUU2Y6jRYyk6toD_Af81zzb-ehED4NLFL24TpXfL8_vOe8Dode5NrkKRRbkjJKAGR4HKovBVYkiqQnJmeQ2wfnTJDqbsQ9zPu829F12yUod6l9b80r-B1WQAa42S_YfkG0nBQGcA75wBITheCOMh6ej88DHcoPdeFksqqvqBzzzUpbVxU-bi9XXZilB6CPfXLJVWdnSzH27oK2aWOTCZomYPgCovy-qorR9Ay4KVTSRkLJvdwiM75vjI9HBzwddaauLWN4sN43cib0HYN9yZuxCBr6tOya-XzuJrNdNN6beuZ4XEibvLnxZ-wbKzRpbb1EMXDyFzzD1miy0YYuU-h49h2aLrFHFZINylG8o1oHtTrpV5RNqK6ZqUS4JF4SqbmFrPuZPPqej2XicTofz6W20G4JDARpx9-jj8enXZtWOEuq67rV_qyllS5O33dzXjZe_PBKwT5ZN3xhnn0zvo3u1Y4GPPEseoFumfIjubpSbfIR-X-MLbvmCO77gli_v8AZbcMMWDGzBni24Ywvu2AKnWGLHFuzYgqscd2zBni2P0Ww0nJ6cBXUrjkAzQlcBzwhYU4KbwSAi2mYfCxmzPJQqsvX_hWZxnCkRGaGjnFOwIrW2-x0C1D_NQLKHdsqqNPsIxzLhQhEdx9owxkKlSS7ASRGGJZkaJD30pnnGqa7r1Nt2KZepi5egSXoiJucOj-MeetWOXfjqLFtHHTRQpfXbe5WGMIjxkHDSQy_by6Bb7QczWRp4TmloSyPxEHzqHnriIW5vQ20NgtD-eg8wb8UdV57eYNpn6E73vhygndVybZ6DkbtSL2p-_gFLRqwh |
| linkProvider | Royal Society of Chemistry |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EGFR-targeted+liposomal+nanohybrid+cerasomes%3A+theranostic+function+and+immune+checkpoint+inhibition+in+a+mouse+model+of+colorectal+cancer&rft.jtitle=Nanoscale&rft.au=Li%2C+Yuan&rft.au=Du%2C+Yang&rft.au=Liang%2C+Xiaolong&rft.au=Sun%2C+Ting&rft.date=2018-09-13&rft.issn=2040-3372&rft.eissn=2040-3372&rft.volume=10&rft.issue=35&rft.spage=16738&rft_id=info:doi/10.1039%2Fc8nr05803b&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-3364&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-3364&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-3364&client=summon |